Harrow Health, Inc. (HROW)
USD 24.4
(1.29%)
USD 24.4
(1.29%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 241.75 Million USD | 85.77% |
| 2022 | 130.13 Million USD | 48.9% |
| 2021 | 87.39 Million USD | 185.19% |
| 2020 | 30.64 Million USD | -3.22% |
| 2019 | 31.66 Million USD | 28.21% |
| 2018 | 24.7 Million USD | 15.95% |
| 2017 | 21.3 Million USD | 2.34% |
| 2016 | 20.81 Million USD | 34.15% |
| 2015 | 15.51 Million USD | 641.66% |
| 2014 | 2.09 Million USD | 221.54% |
| 2013 | 650.62 Thousand USD | -8.31% |
| 2012 | 709.55 Thousand USD | -61.87% |
| 2011 | 1.86 Million USD | 33.83% |
| 2010 | 1.39 Million USD | 27.0% |
| 2009 | 1.09 Million USD | 43.31% |
| 2008 | 763.99 Thousand USD | 1.83% |
| 2007 | 750.24 Thousand USD | 15056.38% |
| 2006 | 4950.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 235.33 Million USD | -2.66% |
| 2024 Q2 | 248.45 Million USD | 5.58% |
| 2023 Q3 | 210.66 Million USD | 4.32% |
| 2023 Q1 | 195.97 Million USD | 50.59% |
| 2023 FY | 241.75 Million USD | 85.77% |
| 2023 Q4 | 241.75 Million USD | 14.76% |
| 2023 Q2 | 201.93 Million USD | 3.04% |
| 2022 Q4 | 130.13 Million USD | 32.62% |
| 2022 FY | 130.13 Million USD | 48.9% |
| 2022 Q3 | 98.13 Million USD | 5.89% |
| 2022 Q1 | 87.85 Million USD | 0.53% |
| 2022 Q2 | 92.66 Million USD | 5.47% |
| 2021 Q1 | 28.38 Million USD | -7.39% |
| 2021 FY | 87.39 Million USD | 185.19% |
| 2021 Q2 | 84.11 Million USD | 196.38% |
| 2021 Q3 | 86.56 Million USD | 2.91% |
| 2021 Q4 | 87.39 Million USD | 0.96% |
| 2020 Q1 | 31.86 Million USD | 0.63% |
| 2020 FY | 30.64 Million USD | -3.22% |
| 2020 Q4 | 30.64 Million USD | -11.28% |
| 2020 Q3 | 34.54 Million USD | 1.42% |
| 2020 Q2 | 34.05 Million USD | 6.88% |
| 2019 FY | 31.66 Million USD | 28.21% |
| 2019 Q1 | 29.47 Million USD | 19.34% |
| 2019 Q2 | 30.15 Million USD | 2.32% |
| 2019 Q3 | 30.97 Million USD | 2.69% |
| 2019 Q4 | 31.66 Million USD | 2.25% |
| 2018 Q1 | 21.11 Million USD | -0.87% |
| 2018 Q3 | 23.83 Million USD | 5.49% |
| 2018 Q4 | 24.7 Million USD | 3.62% |
| 2018 FY | 24.7 Million USD | 15.95% |
| 2018 Q2 | 22.59 Million USD | 7.01% |
| 2017 Q2 | 19.95 Million USD | -2.98% |
| 2017 FY | 21.3 Million USD | 2.34% |
| 2017 Q4 | 21.3 Million USD | -5.18% |
| 2017 Q3 | 22.46 Million USD | 12.61% |
| 2017 Q1 | 20.56 Million USD | -1.22% |
| 2016 Q2 | 16.44 Million USD | -0.49% |
| 2016 FY | 20.81 Million USD | 34.15% |
| 2016 Q4 | 20.81 Million USD | 11.4% |
| 2016 Q3 | 18.68 Million USD | 13.65% |
| 2016 Q1 | 16.52 Million USD | 6.48% |
| 2015 Q1 | 3.16 Million USD | 51.48% |
| 2015 Q2 | 11.61 Million USD | 266.49% |
| 2015 Q3 | 12.77 Million USD | 10.01% |
| 2015 Q4 | 15.51 Million USD | 21.44% |
| 2015 FY | 15.51 Million USD | 641.66% |
| 2014 Q2 | 1.83 Million USD | 179.96% |
| 2014 Q3 | 2.12 Million USD | 15.73% |
| 2014 Q4 | 2.09 Million USD | -1.49% |
| 2014 FY | 2.09 Million USD | 221.54% |
| 2014 Q1 | 655.46 Thousand USD | 0.74% |
| 2013 Q1 | 848.54 Thousand USD | 19.59% |
| 2013 FY | 650.62 Thousand USD | -8.31% |
| 2013 Q4 | 650.62 Thousand USD | -38.54% |
| 2013 Q3 | 1.05 Million USD | -4.45% |
| 2013 Q2 | 1.1 Million USD | 30.56% |
| 2012 Q3 | 669.84 Thousand USD | 36.37% |
| 2012 Q1 | 930.49 Thousand USD | -50.0% |
| 2012 Q2 | 491.19 Thousand USD | -47.21% |
| 2012 Q4 | 709.55 Thousand USD | 5.93% |
| 2012 FY | 709.55 Thousand USD | -61.87% |
| 2011 Q3 | 1.64 Million USD | 3.05% |
| 2011 Q2 | 1.59 Million USD | 4.19% |
| 2011 Q1 | 1.53 Million USD | 10.37% |
| 2011 FY | 1.86 Million USD | 33.83% |
| 2011 Q4 | 1.86 Million USD | 12.94% |
| 2010 FY | 1.39 Million USD | 27.0% |
| 2010 Q4 | 1.39 Million USD | -0.66% |
| 2010 Q3 | 1.39 Million USD | -4.73% |
| 2010 Q2 | 1.46 Million USD | 39.41% |
| 2010 Q1 | 1.05 Million USD | -3.74% |
| 2009 Q3 | 901.24 Thousand USD | -12.37% |
| 2009 FY | 1.09 Million USD | 43.31% |
| 2009 Q2 | 1.02 Million USD | -17.4% |
| 2009 Q4 | 1.09 Million USD | 21.48% |
| 2009 Q1 | 1.24 Million USD | 62.98% |
| 2008 Q4 | 763.99 Thousand USD | 25.77% |
| 2008 Q2 | 920.77 Thousand USD | 95.43% |
| 2008 Q3 | 607.46 Thousand USD | -34.03% |
| 2008 FY | 763.99 Thousand USD | 1.83% |
| 2008 Q1 | 471.16 Thousand USD | -37.2% |
| 2007 Q4 | 750.24 Thousand USD | 208.73% |
| 2007 Q3 | 243 Thousand USD | 6163.09% |
| 2007 Q1 | 4950.00 USD | 60.98% |
| 2007 Q2 | 3880.00 USD | -21.62% |
| 2007 FY | 750.24 Thousand USD | 15056.38% |
| 2006 Q3 | 1200.00 USD | 0.0% |
| 2006 FY | 4950.00 USD | 0.0% |
| 2006 Q4 | 3075.00 USD | 156.25% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 74.495% |
| Embecta Corp. | 2.03 Billion USD | 88.127% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 48.746% |
| Dynavax Technologies Corporation | 375.02 Million USD | 35.537% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 63.415% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 65.673% |
| PainReform Ltd. | 2.69 Million USD | -8883.761% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -47.496% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -3837.602% |
| SCYNEXIS, Inc. | 55.45 Million USD | -335.984% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -2528.718% |
| Cosmos Health Inc. | 30.25 Million USD | -699.117% |
| Journey Medical Corporation | 56.49 Million USD | -327.889% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -3837.602% |
| Safety Shot Inc | 3.89 Million USD | -6111.466% |
| Alpha Teknova, Inc. | 38.55 Million USD | -527.099% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -76.628% |
| Bright Green Corporation | 6.43 Million USD | -3655.035% |
| Procaps Group, S.A. | 462.06 Million USD | 47.68% |
| Theratechnologies Inc. | 98.63 Million USD | -145.089% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -2660.998% |
| Biofrontera Inc. | 23.13 Million USD | -944.786% |
| DURECT Corporation | 30.4 Million USD | -695.083% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 50.406% |
| Cronos Group Inc. | 43.73 Million USD | -452.754% |
| OptiNose, Inc. | 194.33 Million USD | -24.4% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 70.423% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -399.026% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -1052.405% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -33.299% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -6308.919% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -360.34% |
| Radius Health, Inc. | 804.29 Million USD | 69.942% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -1657.65% |
| ProPhase Labs, Inc. | 42.54 Million USD | -468.242% |
| Phibro Animal Health Corporation | 725.54 Million USD | 66.68% |
| Procaps Group S.A. | 462.06 Million USD | 47.68% |
| Alvotech | 1.88 Billion USD | 87.158% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -1624.098% |
| Viatris Inc. | 27.21 Billion USD | 99.112% |
| Rockwell Medical, Inc. | 30.88 Million USD | -682.828% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -167.488% |
| SIGA Technologies, Inc. | 57.97 Million USD | -316.979% |
| Tilray Brands, Inc. | 892.11 Million USD | 72.901% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | -9.988% |
| Shineco, Inc. | 47.6 Million USD | -407.866% |
| PetIQ, Inc. | 645.22 Million USD | 62.532% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -110032.02% |
| Incannex Healthcare Limited | 5.83 Million USD | -4046.707% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 76.285% |
| Alimera Sciences, Inc. | 107.35 Million USD | -125.192% |
| Silver Spike Investment Corp. | 3 Million USD | -7932.112% |
| Assertio Holdings, Inc. | 148.41 Million USD | -62.889% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -12650.921% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -1034.151% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -3340.834% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -2747.325% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -39.43% |
| Hempacco Co., Inc. | 18.82 Million USD | -1184.39% |
| Talphera, Inc. | 6.29 Million USD | -3743.45% |
| Alvotech | 1.88 Billion USD | 87.158% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -40.065% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 71.056% |
| Currenc Group, Inc. | 177.67 Million USD | -36.064% |
| Kamada Ltd. | 109.96 Million USD | -119.839% |
| Indivior PLC | 1.95 Billion USD | 87.61% |
| Evoke Pharma, Inc. | 9.64 Million USD | -2405.71% |
| Flora Growth Corp. | 17.22 Million USD | -1303.745% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -2747.325% |
| Evolus, Inc. | 209.68 Million USD | -15.292% |
| HUTCHMED (China) Limited | 536.38 Million USD | 54.929% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 72.323% |
| Akanda Corp. | 12.66 Million USD | -1808.242% |